Keytruda and Padcev could become cancer’s power couple

The two blockbusters have made a big difference in bladder cancer survival, but will their chemistry hold up when tested in other types?
AOL

Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences

Summit Therapeutics Inc. (NASDAQ:SMMT), on Sunday, revealed the updated overall survival (OS) results from the global Phase 3 HARMONi trial of ivonescimab at the 2025 World Conference on Lung Cancer ...
Healthline

Keytruda Qlex Overview: Side Effects, Uses, Dosage, and More

Keytruda Qlex (pembrolizumab and berahydaluronidas alfa-pmph) is a prescription drug approved to treat different types of cancer, such as non-small cell lung cancer and head and neck cancer. Keytruda ...
Seeking Alpha

KEYTRUDA® (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC)

Five-year exploratory follow-up analysis of KEYNOTE-671 continued to show clinically meaningful improvements in overall survival and event-free survival with KEYTRUDA plus chemotherapy before surgery, ...
Seeking Alpha

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients ...

Late-breaking results from the Phase 3 KEYNOTE-B15 trial were selected for the official Press Program and will be presented at the 2026 American Society of Clinical Oncology (ASCO) Genitourinary (GU) ...
Morningstar

Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 ...

Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1 ...
The Bakersfield Californian

Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 ...

Synthekine Inc., an engineered cytokine therapeutics company, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the ...